🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Listening to Dr Wan and Spira’s presentations - are the number of KRas G12C targeting drugs just Spiraling out of control? That being said- great to see high activity/combinability of olomorasib and other drugs!

Robust OS benefit overall from just 3 rounds of neoadj chemo-IO for resectable st 1b-3a NSCLC with unprecedented OS for pts reaching a pathCR (95% OS at 5 yrs- i am 100% this is just stunning and practice-guiding!) I’d say this is an excellent Forde model many of our patients

Congrats on terrific presentation for Dr. Chaft Jamie Chaft on the 3-arm NEOADAURA trial showing much improved MPR/nodal downstaging by neoadj osi and chemo/osi vs chemo alone (which is pitiful on its own btw..) and excellent EFS for pts achieving MPR We will be scratching our

I just wanted to add that a discussion in Irish rogue spices a presentation up nicely just like adding whiskey to Irish coffee does! Patrick Forde☘️☘️☘️

IMForte trial of atezo+- lurbinectidine for pts w ES-SCLC (note no CNS disease) Expected PFS and (as pleasant surprise) quite notable OS benefit linked w fair toxicity/ easy implementation makes me believe that this regimen will immediately Jazz up the ES-SCLC landscape as the

STARlatamab!!! A star is born at #ASCO25 for the treatment of SCLC! 👏👏👏 Charlie Rudin Giannis Mountzios

What was your best moment at #ASCO25? For me as a 25-year @asco member who has yet to miss a meeting- it was seeing someone with a 50-yr ASCO member batch… and this person still looked quite good! As i am waiting for early flight to get back to clinic to implement progress

Oncologists Arriving at ASCO Returning from ASCO #ASCO25

The situation around liquid biopsy testing is always how should i say… “fluid”- but as a big enthusiast my trust is solid that its use will continue to expand However, definitely disease/context specific IMO for NSCLC the current clinical validity/utility chart goes: ✅to

Taxotere down 2 sets to 1 against any novel agent in st4 NSCLC- 2nd positive interim PFS readout! #lcsm